ASP6981 + Placebo

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Schizophrenia

Conditions

Schizophrenia

Trial Timeline

Jan 22, 2018 โ†’ May 30, 2018

About ASP6981 + Placebo

ASP6981 + Placebo is a phase 1 stage product being developed by Astellas Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03356639. Target conditions include Schizophrenia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03356639Phase 1Completed

Competing Products

20 competing products in Schizophrenia

See all competitors
ProductCompanyStageHype Score
antipsychotic dose increaseEli LillyPre-clinical
23
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + AripiprazoleEli LillyApproved
85
olanzapine therapyEli LillyApproved
85
olanzapine-RAIM + placeboEli LillyPhase 2
52
Clozapine + OlanzapineEli LillyApproved
85
AtomoxetineEli LillyApproved
85
Risperidone + Placebo + LY2140023Eli LillyPhase 2
52
Olanzapine + olanzapine + risperidoneEli LillyApproved
85
Zotepine + RisperidoneAstellas PharmaApproved
85
ASP4345 + Matching PlaceboAstellas PharmaPhase 1
33
ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidoneAstellas PharmaPhase 2
52
SAPHRIS + AsenapineSun PharmaceuticalPhase 1
33
Torrent's Quetiapine Fumarate TabletsTorrent PharmaceuticalsPhase 1
33
Olanzapine HydrochlorideEli LillyPhase 1/2
41
Rapid-Acting Intramuscular Olanzapine + PlaceboEli LillyPhase 3
77
Pomaglumetad methionilEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
Intramuscular Olanzapine Depot + PlaceboEli LillyPhase 3
77
olanzapine + atomoxetine + placeboEli LillyPhase 1/2
41